

DAFTAR PUSTAKA

- Aebi, S., Karlsson, P., & Wapnir, I. L. (2022). Locally advanced breast cancer. *The Breast*, 62, S58–S62. <https://doi.org/10.1016/j.breast.2021.12.011>
- Albuquerque, R. B., Borba, M. A. S. M., Fernandes, M. S. S., Filgueira, T. O., Martins, D. B. G., Filho, J. L. L., Castoldi, A., & Souto, F. O. (2023). Interleukin-33 expression on treatment outcomes and prognosis in Brazilian breast cancer patients undergoing neoadjuvant chemotherapy. *International Journal of Molecular Sciences*, 24(22), 16326. <https://doi.org/10.3390/ijms242216326>
- Andreone, S., et al. (2020). Anti-tumorigenic activities of IL-33: A mechanistic insight. *Frontiers in Immunology*, 11, 571593. <https://doi.org/10.3389/fimmu.2020.571593>
- Apetoh, L., et al. (2007). Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. *Nature Medicine*, 13(9), 1050–1059. <https://doi.org/10.1038/nm1622>
- Arrizabalaga, L., Risson, A., Ezcurra-Hualde, M., Aranda, F., & Berraondo, P. (2024). Unveiling the multifaceted antitumor effects of interleukin 33. *Frontiers in Immunology*, 15, 1425282. <https://doi.org/10.3389/fimmu.2024.1425282>
- Asrat, S., et al. (2023). IL-33 initiates and amplifies both type 1 and type 2 inflammation. *Journal of Allergy and Clinical Immunology*, 151(2), AB126. <https://doi.org/10.1016/j.jaci.2022.12.397>
- Barbieri, E., Gentile, D., Bottini, A., Sagona, A., Gatzemeier, W., Losurdo, A., Fernandes, B., & Tinterri, C. (2021). Neo-adjuvant chemotherapy in luminal, node positive breast cancer: Characteristics, treatment and oncological outcomes: A single center's experience. *European Journal of Breast Health*, 17(4), 356–362. <https://doi.org/10.4274/ejbh.galenos.2021.2021-4-8>
- Baskin, A. S., et al. (2024). The neoadjuvant approach to treatment of breast cancer: Multidisciplinary management to improve outcomes. *Surgical Oncology Insight*, 1(2), 100059. <https://doi.org/10.1016/j.soi.2024.100059>
- Bayles, C. E., et al. (2023). Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology. *Toxicology and Applied Pharmacology*, 459, 116362. <https://doi.org/10.1016/j.taap.2022.116362>
- Benitez Fuentes, J. D., et al. (2024). Global stage distribution of breast cancer at diagnosis: A systematic review and meta-analysis. *JAMA Oncology*, 10(1), 71. <https://doi.org/10.1001/jamaoncol.2023.4837>
- Beretta, G. L., Cassinelli, G., Rossi, G., Azzariti, A., Corbeau, I., Tosi, D., & Perego, P. (2025). Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies. *Drug Resistance Updates*, 81, 101223. <https://doi.org/10.1016/j.drug.2025.101223>

- Bhardwaj, P. V., et al. (2023). Outcomes of a multidisciplinary team in the management of patients with early-stage breast cancer undergoing neoadjuvant chemotherapy at a community cancer center. *Current Oncology*, 30(5), 4861–4870. <https://doi.org/10.3390/currncol30050366>
- Blomberg, O. S., Spagnuolo, L., Garner, H., Voorwerk, L., Isaeva, O. I., van Dyk, E., et al. (2023). IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. *Cancer Cell*, 41(1), 106–123.e10. <https://doi.org/10.1016/j.ccell.2022.11.014>
- Bray, F., et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 74(3), 229–263. <https://doi.org/10.3322/caac.21834>
- Brunner, T. M., et al. (2024). A type 1 immunity-restricted promoter of the IL-33 receptor gene directs antiviral T-cell responses. *Nature Immunology*, 25(2), 256–267. <https://doi.org/10.1038/s41590-023-01697-6>
- Cardoso, F., et al. (2024). 6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). *The Breast*, 76, 103756. <https://doi.org/10.1016/j.breast.2024.103756>
- Cayrol, C. (2021). IL-33, an alarmin of the IL-1 family involved in allergic and non allergic inflammation: Focus on the mechanisms of regulation of its activity. *Cells*, 11(1), 107. <https://doi.org/10.3390/cells11010107>
- Cayrol, C., & Girard, J. (2018). Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. *Immunological Reviews*, 281(1), 154–168. <https://doi.org/10.1111/imr.12619>
- Cayrol, C., & Girard, J.-P. (2022). Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine. *Cytokine*, 156, 155891. <https://doi.org/10.1016/j.cyto.2022.155891>
- Che, K., et al. (2024). Macrophages reprogramming improves immunotherapy of IL-33 in peritoneal metastasis of gastric cancer. *EMBO Molecular Medicine*, 16(2), 251–266. <https://doi.org/10.1038/s44321-023-00012-y>
- Chen, C., Zheng, H., Wang, Y., Tong, Y., Zhang, H., Xie, S., Ma, X., Jiang, M., Gong, Z., Yan, T., Tian, Y., Guo, L., & Lu, R. (2024). Changes in sST2 and NT-proBNP levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline-containing chemotherapies. *Frontiers in Cardiovascular Medicine*, 11, 1477679. <https://doi.org/10.3389/fcvm.2024.1477679>
- Choi, M.-R., Sosman, J. A., & Zhang, B. (2021). The Janus face of IL-33 signaling in tumor development and immune escape. *Cancers*, 13(13), 3281. <https://doi.org/10.3390/cancers13133281>

- Clark, J. T., et al. (2021). IL-33 promotes innate lymphoid cell-dependent IFN- γ production required for innate immunity to *Toxoplasma gondii*. *eLife*, 10, e65614. <https://doi.org/10.7554/eLife.65614>
- Collins, P. M., O'Neill, A., McGreal, G., & Kerin, M. J. (2021). Neoadjuvant chemotherapy for luminal A breast cancer: Factors predictive of histopathologic response and oncologic outcome. *The American Journal of Surgery*, 222(2), 368–376. <https://doi.org/10.1016/j.amjsurg.2020.11.053>
- Criscitiello, C., et al. (2014). Immune approaches to the treatment of breast cancer, around the corner? *Breast Cancer Research*, 16(1), 204. <https://doi.org/10.1186/bcr3620>
- Cruz-Ausejo, L., et al. (2023). Can working at home be a hazard? Ergonomic factors associated with musculoskeletal disorders among teleworkers during the COVID-19 pandemic: A scoping review. *International Journal of Occupational Safety and Ergonomics*, 29(4), 1335–1344. <https://doi.org/10.1080/10803548.2022.2127246>
- Denkert, C., et al. (2018). Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy. *The Lancet Oncology*, 19(1), 40–50. [https://doi.org/10.1016/S1470-2045\(17\)30904-X](https://doi.org/10.1016/S1470-2045(17)30904-X)
- Derouane, F., et al. (2022). Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: Current and future perspectives for precision medicine. *Cancers*, 14(16), 3876. <https://doi.org/10.3390/cancers14163876>
- Dhanushkodi, M., et al. (2021). Locally advanced breast cancer (LABC): Real-world outcome of patients from Cancer Institute, Chennai. *JCO Global Oncology*, 7, 767–781. <https://doi.org/10.1200/GO.21.00001>
- Eberhardt, A., et al. (2023). IL-33 drives polyfunctionality and antitumor activity of a unique ST2+ NK cell population. *bioRxiv* (Preprint). <https://doi.org/10.1101/2023.02.14.528486>
- Fan, G., Zuo, S., Wang, Z., Zhang, S., Liu, L., Luo, H., Xie, Y., Zhang, Y., & Li, D. (2025). Targeting of the IL-33/Wnt axis restricts breast cancer stemness and metastasis. *Scientific Reports*, 15, 18172. <https://doi.org/10.1038/s41598-025-03260-9>
- Fazzini, L., Angius, S., Campana, N., Pascalis, L., Deidda, M., Pugliesi, G. M., Quagliariello, V., Maurea, N., Tocchetti, C. G., Ameri, P., & Cadeddu Dessalvi, C. (2025). Soluble suppression of tumorigenicity-2 changes during cardiotoxic cancer treatment: A systematic review and meta-analysis. *Frontiers in Cardiovascular Medicine*, 12, 1624023. <https://doi.org/10.3389/fcvm.2025.1624023>
- Feng, Z., et al. (2024). Exogenous IL-33 promotes tumor immunity via macroscopic regulation of ILC2s. *Scientific Reports*, 14(1), 26140. <https://doi.org/10.1038/s41598-024-77751-6>
- Ferretti, R., et al. (2021). Tumor cell invasion into Matrigel: Optimized protocol for RNA extraction. *BioTechniques*, 70(6), 327–335. <https://doi.org/10.2144/btn-2021-0001>

- Fu, M., et al. (2025). Current and future burden of breast cancer in Asia: A GLOBOCAN data analysis for 2022 and 2050. *The Breast*, 79, 103835. <https://doi.org/10.1016/j.breast.2024.103835>
- Garrone, O., et al. (2020). Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: The TRANSERI-GONO study. *ESMO Open*, 5(5), e000876. <https://doi.org/10.1136/esmoopen-2020-000876>
- Goda, N., et al. (2022). The effect of intratumoral interrelation among FOXP3+ regulatory T cells on treatment response and survival in triple-negative breast cancer. *Cancers*, 14(9), 2138. <https://doi.org/10.3390/cancers14092138>
- Golshan, M., et al. (2020). Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from the BrightNess randomized clinical trial. *JAMA Surgery*, 155(3), e195410. <https://doi.org/10.1001/jamasurg.2019.5410>
- Gradishar, W. J., et al. (2024). Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network*, 22(5), 331–357. <https://doi.org/10.6004/jnccn.2024.0035>
- Groysman, L., et al. (2021). Chemotherapy-induced cytokines and prognostic gene signatures vary across breast and colorectal cancer. *American Journal of Cancer Research*, 11(12), 6086–6106.
- Gu, T.-Q., Xiao, Y.-L., & Shao, Z.-M. (2024). Intratumor heterogeneity in breast cancer: Tracing its origins and translating findings into clinical practice. *Precision Medicine and Engineering*, 1(1), 100006. <https://doi.org/10.1016/j.preme.2024.100006>
- Guerin, C. J. (2023). Using antibodies in microscopy: A guide to immunohistochemistry. Part 2: IHC staining protocols. *Microscopy Today*, 31(3), 34–39. <https://doi.org/10.1093/mictod/qaad029>
- Guo, L., et al. (2023). Breast cancer heterogeneity and its implication in personalized precision therapy. *Experimental Hematology & Oncology*, 12(1), 3. <https://doi.org/10.1186/s40164-022-00363-1>
- Habanjar, O., et al. (2023). Crosstalk of inflammatory cytokines within the breast tumor microenvironment. *International Journal of Molecular Sciences*, 24(4), 4002. <https://doi.org/10.3390/ijms24044002>
- Haghbin, M., et al. (2023). Comparison of interleukin-33 serum levels in patients with breast cancer and idiopathic granulomatous mastitis. *Asian Pacific Journal of Cancer Prevention*, 24(5), 1629–1634. <https://doi.org/10.31557/APJCP.2023.24.5.1629>
- Hanahan, D. (2022). Hallmarks of cancer: New dimensions. *Cancer Discovery*, 12(1), 31–46. <https://doi.org/10.1158/2159-8290.CD-21-1059>
- Hanson, S. E., et al. (2022). Long-term quality of life in patients with breast cancer after breast conservation vs mastectomy and reconstruction. *JAMA Surgery*, 157(6), e220631. <https://doi.org/10.1001/jamasurg.2022.0631>
- Hassan, M., et al. (2024). Non-genetic heterogeneity and immune subtyping in breast cancer: Implications for immunotherapy and targeted

- therapeutics. *Translational Oncology*, 47, 102055. <https://doi.org/10.1016/j.tranon.2024.102055>
- He, P.-Y., Wu, M.-Y., Zheng, L.-Y., Duan, Y., Fan, Q., Zhu, X.-M., & Yao, Y.-M. (2024). Interleukin-33/serum stimulation-2 pathway: Regulatory mechanisms and emerging implications in immune and inflammatory diseases. *Cytokine & Growth Factor Reviews*, 76, 112–126. <https://doi.org/10.1016/j.cytofr.2023.12.001>
- Ignatiadis, M., et al. (2019). Tumor-infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy. *JNCI: Journal of the National Cancer Institute*, 111(1), 69–77. <https://doi.org/10.1093/jnci/djy076>
- Imran, M., Saleem, S., Chaudhuri, A., Ali, J., & Baboota, S. (2020). Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer. *Journal of Drug Delivery Science and Technology*, 60, 101959. <https://doi.org/10.1016/j.jddst.2020.101959>
- Jafarzadeh, A., et al. (2015). Evaluation of the circulating levels of IL-12 and IL-33 in patients with breast cancer: Influences of the tumor stages and cytokine gene polymorphisms. *Iranian Journal of Basic Medical Sciences*, 18(12), 1189–1198.
- Janssens, S., Rennen, S., & Agostinis, P. (2024). Decoding immunogenic cell death from a dendritic cell perspective. *Immunological Reviews*, 321(1), 350–370. <https://doi.org/10.1111/imr.13301>
- Jivani, A., & Shinde, R. K. (2024). A comprehensive review of taxane treatment in breast cancer: Clinical perspectives and toxicity profiles. *Cureus* (Preprint). <https://doi.org/10.7759/cureus.59266>
- Joshi, S., et al. (2024). Determinants of pathological complete response to neoadjuvant chemotherapy in breast cancer: A single-institution experience. *Indian Journal of Cancer*, 61(2), 324–331. https://doi.org/10.4103/ijc.IJC_813_20
- Jovanovic, M. Z., et al. (2022). Dual blockage of PD-L/PD-1 and IL33/ST2 axes slows tumor growth and improves antitumor immunity by boosting NK cells. *Life Sciences*, 289, 120214. <https://doi.org/10.1016/j.lfs.2021.120214>
- Kang, B. H., et al. (2025). Unlocking IL-33: New insights into tumor immunity. *Immune Network*, 25, e36. <https://doi.org/10.4110/in.2025.25.e36>
- Kang, M., & Bae, Y. (2024). IL-33 and IL-33-derived DC-based tumor immunotherapy. *Experimental & Molecular Medicine*. <https://doi.org/10.1038/s12276-024-01249-4>
- Kartikasari, A. E. R., et al. (2021). Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis. *Frontiers in Oncology*, 11, 692142. <https://doi.org/10.3389/fonc.2021.692142>
- Kim, J., et al. (2025). Global patterns and trends in breast cancer incidence and mortality across 185 countries. *Nature Medicine* (Preprint). <https://doi.org/10.1038/s41591-025-03502-3>

- Korde, L. A., et al. (2021). Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. *Journal of Clinical Oncology*, 39(13), 1485–1505. <https://doi.org/10.1200/JCO.20.03399>
- Krüger, K., et al. (2021). Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer. *Scientific Reports*, 11(1), 3388. <https://doi.org/10.1038/s41598-021-81914-0>
- Kuncman, W., et al. (2021). Intertumoral heterogeneity of primary breast tumors and synchronous axillary lymph node metastases reflected in IHC-assessed expression of routine and nonstandard biomarkers. *Frontiers in Oncology*, 11, 660318. <https://doi.org/10.3389/fonc.2021.660318>
- Kureshi, C. T., & Dougan, S. K. (2025). Cytokines in cancer. *Cancer Cell*, 43(1), 15–35. <https://doi.org/10.1016/j.ccell.2024.11.011>
- Lamorte, S., Quevedo, R., Jin, R., Neufeld, L., Liu, Z. Q., Ciudad, M. T., Lukhele, S., Bruce, J., Mishra, S., Zhang, X., Saeed, Z. K., Berman, H., Philpott, D. J., Girardin, S. E., Harding, S., Munn, D. H., Mak, T. W., Karlsson, M. C. I., Brooks, D. G., & McGaha, T. L. (2025). Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33. *Cancer Cell*, 43(5), 955–969.e10. <https://doi.org/10.1016/j.ccell.2025.02.017>
- Larsen, K. M., et al. (2018). The role of IL-33/ST2 pathway in tumorigenesis. *International Journal of Molecular Sciences*, 19(9), 2676. <https://doi.org/10.3390/ijms19092676>
- Lee, J., & Kim, E. J. (2021). ST2 as a biomarker to show the preventive effect of exercise in myocardial injury by doxorubicin? *International Journal of Heart Failure*, 3(2), 117–120. <https://doi.org/10.36628/ijhf.2021.0003>
- Li, L., et al. (2017). Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: A systematic review and meta-analysis. *Future Oncology*, 13(11), 1021–1034. <https://doi.org/10.2217/fon-2016-0428>
- Liefwaard, M. C., et al. (2024). Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade. *npj Breast Cancer*, 10(1), 29. <https://doi.org/10.1038/s41523-024-00636-4>
- Lim, B., et al. (2018). Inflammatory breast cancer biology: The tumour microenvironment is key. *Nature Reviews Cancer*, 18(8), 485–499. <https://doi.org/10.1038/s41568-018-0010-y>
- Livingston-Rosanoff, D., et al. (2019). Does tumor size predict response to neoadjuvant chemotherapy in the modern era of biologically driven treatment? A nationwide study of US breast cancer patients. *Clinical Breast Cancer*, 19(6), e741–e747. <https://doi.org/10.1016/j.clbc.2019.05.014>
- Loibl, S., et al. (2018). Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant

- chemotherapy in triple-negative breast cancer (BrighTNess): A randomised, phase 3 trial. *The Lancet Oncology*, 19(4), 497–509. [https://doi.org/10.1016/S1470-2045\(18\)30111-6](https://doi.org/10.1016/S1470-2045(18)30111-6)
- Loibl, S., et al. (2024). Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. *Annals of Oncology*, 35(2), 159–182. <https://doi.org/10.1016/j.annonc.2023.11.016>
- Löönd, F., Tiede, S., & Christofori, G. (2021). Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. *British Journal of Cancer*, 125(2), 164–175. <https://doi.org/10.1038/s41416-021-01328-7>
- Macleod, T., et al. (2021). The immunological impact of IL-1 family cytokines on the epidermal barrier. *Frontiers in Immunology*, 12, 808012. <https://doi.org/10.3389/fimmu.2021.808012>
- Mahlaköiv, T., et al. (2019). Stromal cells maintain immune cell homeostasis in adipose tissue via production of interleukin-33. *Science Immunology*, 4(35), eaax0416. <https://doi.org/10.1126/sciimmunol.aax0416>
- Maiques, O., & Sanz-Moreno, V. (2022). Multiplex chromogenic immunohistochemistry to stain and analyze paraffin tissue sections from the mouse or human. *STAR Protocols*, 3(4), 101879. <https://doi.org/10.1016/j.xpro.2022.101879>
- Malhotra, S., & Tadros, A. B. (2024). New strategies for locally advanced breast cancer: A review of inflammatory breast cancer and nonresponders. *Clinical Breast Cancer*, 24(4), 301–309. <https://doi.org/10.1016/j.clbc.2024.01.009>
- Mora Barthelmess, R., Stijlemans, B., & Van Ginderachter, J. A. (2023). Hallmarks of cancer affected by the MIF cytokine family. *Cancers*, 15(2), 395. <https://doi.org/10.3390/cancers15020395>
- Muñoz-Castro, C., et al. (2023). Cyclic multiplex fluorescent immunohistochemistry protocol to phenotype glial cells in formalin-fixed paraffin-embedded human brain sections. In A. E. Kalyuzhny (Ed.), *Signal transduction immunohistochemistry* (Methods in Molecular Biology, pp. 283–305). Springer US. https://doi.org/10.1007/978-1-0716-2811-9_19
- Murchison, S., & Truong, P. (2021). Locoregional therapy in breast cancer patients treated with neoadjuvant chemotherapy. *Expert Review of Anticancer Therapy*, 21(8), 865–875. <https://doi.org/10.1080/14737140.2021.1903876>
- Nan, Y., Bai, Y., Hu, X., et al. (2024). Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy. *Journal for ImmunoTherapy of Cancer*, 12(9), e009236. <https://doi.org/10.1136/jitc-2024-009236>
- Ondracek, R. P., et al. (2022). Results and lessons from dual extraction of DNA and RNA from formalin-fixed paraffin-embedded breast tumor tissues for a large cancer epidemiologic study. *BMC Genomics*, 23(1), 614. <https://doi.org/10.1186/s12864-022-08837-6>
- Orrantia-Borunda, E., et al. (2022). Subtypes of breast cancer. In Department of Medical Education, Dr. Kiran C. Patel College of

- Allopathic Medicine, Nova Southeastern University & H. N. Mayrovitz (Eds.), *Breast cancer* (pp. 31–42). Exon Publications. <https://doi.org/10.36255/exon-publications-breast-cancer-subtypes>
- Pandurangappa, V., et al. (2023). Assessment of response to neoadjuvant chemotherapy in locally advanced breast carcinoma using image-guided clip placement. *Cureus* (Preprint). <https://doi.org/10.7759/cureus.47763>
- Pavitra, E., et al. (2023). The role of NF-κB in breast cancer initiation, growth, metastasis, and resistance to chemotherapy. *Biomedicine & Pharmacotherapy*, 163, 114822. <https://doi.org/10.1016/j.biopha.2023.114822>
- Perri, G., et al. (2024). Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation. *Cancer Immunology, Immunotherapy*, 73(6), 110. <https://doi.org/10.1007/s00262-024-03676-8>
- Ramón y Cajal, S., et al. (2020). Clinical implications of intratumor heterogeneity: Challenges and opportunities. *Journal of Molecular Medicine*, 98(2), 161–177. <https://doi.org/10.1007/s00109-020-01874-2>
- Remnant, L., et al. (2021). The intrinsically disorderly story of Ki-67. *Open Biology*, 11(8), 210120. <https://doi.org/10.1098/rsob.210120>
- Rosenberg, S. M., et al. (2020). Association of breast cancer surgery with quality of life and psychosocial well-being in young breast cancer survivors. *JAMA Surgery*, 155(11), 1035. <https://doi.org/10.1001/jamasurg.2020.3325>
- Senkus, E., & Łacko, A. (2018). Locally advanced breast cancer. In L. Wyld et al. (Eds.), *Breast cancer management for surgeons* (pp. 567–578). Springer International Publishing. https://doi.org/10.1007/978-3-319-56673-3_48
- Shani, O., Vorobyov, T., Monteran, L., Lavie, D., Cohen, N., Raz, Y., et al. (2020). Fibroblast-derived IL-33 facilitates breast cancer metastasis by modifying the immune microenvironment and driving type 2 immunity. *Cancer Research*, 80(23), 5317–5329. <https://doi.org/10.1158/0008-5472.CAN-20-2116>
- Song, D., Lian, Y., & Zhang, L. (2023). The potential of activator protein 1 (AP-1) in cancer targeted therapy. *Frontiers in Immunology*, 14, 1224892. <https://doi.org/10.3389/fimmu.2023.1224892>
- Spring, L. M., et al. (2020). Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis. *Clinical Cancer Research*, 26(12), 2838–2848. <https://doi.org/10.1158/1078-0432.CCR-19-3492>
- Stojanovic, B., et al. (2023). Decoding the IL-33/ST2 axis: Its impact on the immune landscape of breast cancer. *International Journal of Molecular Sciences*, 24(18), 14026. <https://doi.org/10.3390/ijms241814026>

- Tanei, T., et al. (2024). High HER2 intratumoral heterogeneity is a predictive factor for poor prognosis in early-stage and locally advanced HER2-positive breast cancer. *Cancers*, 16(5), 1062. <https://doi.org/10.3390/cancers16051062>
- Tse, T., et al. (2021). Neoadjuvant chemotherapy in breast cancer: Review of the evidence and conditions that facilitated its use during the global pandemic. *Current Oncology*, 28(2), 1338–1347. <https://doi.org/10.3390/currncol28020127>
- Urueña, C., Lasso, P., Bernal-Estevez, D., Rubio, D., Salazar, A. J., Olaya, M., Barreto, A., Tawil, M., Torregrosa, L., & Fiorentino, S. (2022). The breast cancer immune microenvironment is modified by neoadjuvant chemotherapy. *Scientific Reports*, 12, 7981. <https://doi.org/10.1038/s41598-022-12108-5>
- Van der Zanden, S. Y., Qiao, X., & Neefjes, J. (2021). New insights into the activities and toxicities of the old anticancer drug doxorubicin. *The FEBS Journal*, 288(21), 6095–6111. <https://doi.org/10.1111/febs.15583>
- Von Minckwitz, G., et al. (2019). Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *New England Journal of Medicine*, 380(7), 617–628. <https://doi.org/10.1056/NEJMoa1814017>
- Wahidin, M., et al. (2022). Twelve years implementation of cervical and breast cancer screening program in Indonesia. *Asian Pacific Journal of Cancer Prevention*, 23(3), 829–837. <https://doi.org/10.31557/APJCP.2022.23.3.829>
- Whitaker, R. H., & Cook, J. G. (2021). Stress relief techniques: p38 MAPK determines the balance of cell cycle and apoptosis pathways. *Biomolecules*, 11(10), 1444. <https://doi.org/10.3390/biom11101444>
- Xianyu, C., et al. (2017). The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: A systematic review and meta-analysis. *Future Oncology*, 13(9), 843–857. <https://doi.org/10.2217/fon-2016-0420>
- Yang, Z.-P., et al. (2015). The association of serum IL-33 and sST2 with breast cancer. *Disease Markers*, 2015, 1–6. <https://doi.org/10.1155/2015/516895>
- Yeoh, W. J., Vu, V. P., & Krebs, P. (2022). IL-33 biology in cancer: An update and future perspectives. *Cytokine*, 157, 155961. <https://doi.org/10.1016/j.cyto.2022.155961>
- Yi, M., et al. (2024). Targeting cytokine and chemokine signaling pathways for cancer therapy. *Signal Transduction and Targeted Therapy*, 9(1), 176. <https://doi.org/10.1038/s41392-024-01868-3>
- Yılmaz, C., et al. (2025). A comprehensive analysis of neoadjuvant chemotherapy in breast cancer: Adverse events, clinical response rates, and surgical and pathological outcomes. *Cancers*, 17(2), 163. <https://doi.org/10.3390/cancers17020163>
- Yu, H., et al. (2022). RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: A systematic

- review and meta-analysis. *BMJ Open*, 12(6), e052294. <https://doi.org/10.1136/bmjopen-2021-052294>
- Zhang, J., Pan, S., Jian, C., Hao, L., Dong, J., Sun, Q., Jin, H., & Han, X. (2021). Immunostimulatory properties of chemotherapy in breast cancer: From immunogenic modulation mechanisms to clinical practice. *Frontiers in Immunology*, 12, 819405. <https://doi.org/10.3389/fimmu.2021.819405>
- Zhang, X., et al. (2020). The contradictory role of interleukin-33 in immune cells and tumor immunity. *Cancer Management and Research*, 12, 7527–7537. <https://doi.org/10.2147/CMAR.S262745>
- Zhao, S., Tang, Y., Wang, R., & Najafi, M. (2022). Mechanisms of cancer cell death induction by paclitaxel: An updated review. *Apoptosis*, 27, 647–667. <https://doi.org/10.1007/s10495-022-01750-z>
- Zhou, Z., Yan, F., & Liu, O. (2020). Interleukin (IL)-33: An orchestrator of immunity from host defence to tissue homeostasis. *Clinical & Translational Immunology*, 9(6), e1146. <https://doi.org/10.1002/cti2.1146>
- Zhu, Y., et al. (2024). ST2L promotes VEGFA-mediated angiogenesis in gastric cancer by activating TRAF6/PI3K/Akt/NF-κB pathway via IL-33. *Scientific Reports*, 14(1), 26393. <https://doi.org/10.1038/s41598-024-76763-6>